SCHEDULE: Venrock Group Discloses 9.9% Stake in Vor Biopharma
Beneficial Ownership Disclosure
A group of Venrock entities and individuals has disclosed a 9.9% beneficial ownership stake in Vor Biopharma Inc., primarily through common stock and pre-funded warrants.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The filing discloses their beneficial ownership of 760,699 shares of Vor Biopharma Inc. common stock.
- This aggregate amount represents 9.9% of Vor Biopharma Inc.'s outstanding common stock, rounded down from 9.99% due to EDGAR filing system limitations.
- The ownership includes direct common stock holdings and pre-funded warrants, which are subject to a "Beneficial Ownership Blocker" limiting exercise to prevent ownership exceeding 9.99% of outstanding common stock.
- The beneficial ownership percentage is calculated based on 6,853,907 shares of common stock outstanding as of September 18, 2025, plus 499,966 shares issued subsequent to September 18, 2025, upon the exercise of pre-funded warrants by the Reporting Persons, and 260,733 shares of common stock issuable upon the exercise of the remaining pre-funded warrants.
Sentiment
Score: 6
Explanation: The disclosure of a significant institutional stake by Venrock is generally a positive signal of investor confidence in Vor Biopharma Inc. However, the beneficial ownership blocker on warrants introduces a minor limitation on the immediate full realization of potential voting or economic power from the warrants.
Positives
- A significant institutional investment group (Venrock) holds a substantial stake, indicating confidence in Vor Biopharma Inc.'s prospects.
- The investment includes pre-funded warrants, providing potential for future capital injection into Vor Biopharma Inc. upon exercise, albeit capped by the beneficial ownership blocker.
Negatives
- The "Beneficial Ownership Blocker" limits the immediate full exercise of all pre-funded warrants, capping the reporting persons' stake at 9.99%.
Risks
- The "Beneficial Ownership Blocker" in the pre-funded warrants prevents the Reporting Persons from immediately exercising warrants that would result in ownership exceeding 9.99% of Vor Biopharma Inc.'s outstanding common stock, potentially limiting their full economic or voting influence from the warrants.
Future Outlook
The filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Vor Biopharma Inc.'s future performance or strategic direction.
Industry Context
This filing indicates continued institutional investor interest in the biopharma sector, with Venrock, a prominent healthcare capital firm, maintaining a significant stake in Vor Biopharma Inc. Such disclosures are common for investors reaching or exceeding 5% ownership thresholds in publicly traded companies.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a 9.9% stake may be viewed positively, potentially signaling confidence in the company's prospects.
- Company Management: Awareness of a large, active institutional investor may influence strategic decisions and corporate governance.
Key Dates
| Date | Description |
|---|---|
| 2025-09-18 | Date of event which requires the filing of the Schedule 13G statement. |
| 2025-09-18 | Date as of which 6,853,907 shares of common stock were outstanding, as reported in the Issuer's Form S-3. |
| 2025-09-24 | Date Vor Biopharma Inc. filed its Registration Statement on Form S-3 with the Securities and Exchange Commission. |
| 2025-09-25 | Date of execution for the Power of Attorney for Bong Koh. |
| 2025-09-25 | Date of execution for the Power of Attorney for Nimish Shah. |
| 2025-09-25 | Date of execution for the Joint Filing Agreement. |
| 2025-09-25 | Date of signing for the Schedule 13G by Sherman G. Souther on behalf of the Reporting Persons. |
Recommendation
holdThe filing indicates a substantial, stable institutional ownership by Venrock, which can be a positive signal. However, it is purely a disclosure of ownership and does not provide new operational or financial performance data for Vor Biopharma Inc. to warrant a 'buy' or 'sell' recommendation. The 'Beneficial Ownership Blocker' on warrants is a minor technical detail for the reporting persons, not a fundamental change for the company. Therefore, a 'hold' recommendation is appropriate, pending further operational updates from Vor Biopharma Inc.
Keywords
Vor Biopharma Inc., Venrock, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biopharma, Investment, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.